The glutamatergic system and Alzheimer's disease: Therapeutic implications

CNS Drugs

Volumn 17, Issue 9, 2003, Pages 641-652

  Butterfield, D Allan ^a   Pocernich, Chava B ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 ADAMANTYLMETHYLAMMONIO) 5 TRIMETHYLAMMONIOPENTANE DIBROMIDE; 1 ADAMANTYLMETHYLAMMONIO 5 AMMONIOPENTANE DIBROMIDE; 2 AMINO 5 PHOSPHONOVALERIC ACID; 2 AMINO 7 PHOSPHONOHEPTANOIC ACID; 4 PHOSPHONOMETHYLPIPECOLIC ACID; 6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; ACETYLCYSTEINE; AMYLOID BETA PROTEIN; ANTIOXIDANT; APTIGANEL; ASPARTIC ACID; CALCIUM CHANNEL BLOCKING AGENT; CHF 3381; CYCLOSERINE; DIZOCILPINE; ESTROGEN; FULVESTRANT; GLUTAMATE RECEPTOR; GLUTAMIC ACID; GLYCINE; HUPERZINE A; IFENPRODIL; MEMANTINE; MILACEMIDE; N (2 INDANYL)GLYCINAMIDE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NIMODIPINE; PHENCYCLIDINE; QUINOLINIC ACID; SPERMIDINE; TOCOPHEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; AMINO ACID BRAIN LEVEL; ANTIOXIDANT ACTIVITY; BRAIN DYSFUNCTION; BRAIN LEVEL; COGNITION; COGNITIVE DEFECT; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG APPROVAL; ESTROGEN THERAPY; GLUTAMATERGIC SYSTEM; HUMAN; INCIDENCE; LEARNING; MEMORY; NEUROTOXICITY; NEUROTRANSMISSION; OXIDATIVE STRESS; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEPTOR UPREGULATION; REVIEW; SIDE EFFECT; SYMPTOMATOLOGY;

ALZHEIMER DISEASE; CELL DEATH; EXCITATORY AMINO ACID AGENTS; GLUTAMIC ACID; HUMANS; LEARNING; MEMANTINE; MEMORY; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0043172479     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200317090-00004     Document Type: Review

References (137)

1. Katzman R, Saitoh T. Advances in Alzheimer's disease. FASEB J 1991; 5: 278-86
2. Katzman R. Epidemiology of Alzheimer's disease. Neurobiol Aging 2000; 21 Suppl.: S1
3. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984; 120: 885-90
4. Masters CL, Simms G, Weinman NA, et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 1985; 82: 4245-9
5. Yankner BA, Dawes LR, Fisher S, et al. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science 1989; 245: 417-20
6. Frautschy SA, Baird A, Cole GM. Effects of injected Alzheimer beta-amyloid cores in rat brain. Proc Natl Acad Sci U S A 1991; 88: 8362-6
7. Kowall NW, Beal MF, Busciglio J, et al. An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P. Proc Natl Acad Sci U S A 1991; 88: 7247-51
8. Pike CJ, Walencewicz AJ, Glabe CG, et al. In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res 1991; 563: 311-4
9. Howlett DR, Jennings KH, Lee DC, et al. Aggregation state and neurotoxic properties of Alzheimer beta-amyloid peptide. Neurodegeneration 1995; 4: 23-32
10. Harris ME, Hensley K, Butterfield DA, et al. Direct evidence of oxidative injury produced by the Alzheimer's beta-amyloid peptide (1-40) in cultured hippocampal neurons. Exp Neurol 1995; 131: 193-202
11. Aksenov MY, Aksenova MV, Butterfield DA, et al. Glutamine synthetase-induced enhancement of beta-amyloid peptide A beta (1-40) neurotoxicity accompanied by abrogation of fibril formation and A beta fragmentation. J Neurochem 1996; 66: 2050-6
12. Aksenov MY, Aksenova MV, Markesbery WR, et al. Amyloid beta-peptide (1-40)-mediated oxidative stress in cultured hippocampal neurons: protein carbonyl formation, CK BB expression, and the level of Cu, Zn, and Mn SOD mRNA. J Mol Neurosci 1998; 10: 181-92
13. Yatin SM, Aksenov M, Butterfield DA. The antioxidant vitamin E modulates amyloid beta-peptide-induced creatine kinase activity inhibition and increased protein oxidation: implications for the free radical hypothesis of Alzheimer's disease. Neurochem Res 1999; 24: 427-35
14. Yatin SM, Varadarajan S, Link C, et al. In vitro and in vivo oxidative stress associated with Alzheimer's amyloid beta-peptide (1-42). Neurobiol Aging 1999; 20: 325-30
15. Yatin SM, Aksenova M, Aksenov M, et al. Effect of transglutaminase on Aβ(1-40) fibril formation and neurotoxicity. Alzheimer Rep 1999; 2: 165-70
16. Varadarajan S, Yatin S, Kanski J, et al. Methionine residue 35 is important in amyloid beta-peptide-associated free radical oxidative stress. Brain Res Bull 1999; 50: 133-41
17. Varadarajan S, Yatin S, Aksenova M, et al. Review: Alzheimer's amyloid-peptide-associated free radical oxidative stress and neurotoxicity. J Struct Biol 2000; 130: 184-208
18. Aksenov MY, Aksenova MV, Harris ME, et al. Enhancement of beta-amyloid peptide A beta(1-40)-mediated neurotoxicity by glutamine synthetase. J Neurochem 1995; 65: 1899-902
19. Yatin SM, Yatin M, Aulick T, et al. Alzheimer's amyloid beta-peptide associated free radicals increase rat embryonic neuronal polyamine uptake and ornithine decarboxylase activity: protective effect of vitamin E. Neurosci Lett 1999; 263: 17-20
20. Selkoe DJ. Amyloid beta-protein and the genetics of Alzheimer's disease. J Biol Chem 1996; 271: 18295-8
21. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996; 8: 864-70
22. Teller JK, Russo C, DeBusk L, et al. Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome. Nat Med 1996; 2: 93-5
23. Games D, Adams D, Alessandrini R, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995; 373: 523-7
24. Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996; 274: 99-102
25. Hsiao K. Transgenic mice expressing Alzheimer amyloid precursor proteins. Exp Gerontol 1998; 33: 883-9
26. Masliah E, Sisk A, Mallory M, et al. Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease. J Neurosci 1996; 16: 5795-811
27. Irizarry MC, McNamara M, Fedorchak K, et al. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol 1997; 56: 965-73
28. Sturchler-Pierrat C, Abramowski D, Duke M, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A 1997; 94: 13287-92
29. Calhoun ME, Wiederhold KH, Abramowski D, et al. Neuron loss in APP transgenic mice. Nature 1998; 395: 755-6
30. Frautschy SA, Yang F, Irrizarry M, et al. Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol 1998; 152: 307-17
31. Pappolla MA, Chyan YJ, Omar RA, et al. Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am J Pathol 1998; 152: 871-7
32. Smith MA, Hirai K, Hsiao K, et al. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 1998; 70: 2212-5
33. Lambert MP, Barlow AK, Chromy BA, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 1998; 95: 6448-53
34. Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416: 535-9
35. Drake J, Link CD, Butterfield DA. Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid β-peptide (1-42) in a transgenic Caenorhabditis elegans model. Neurobiol Aging 2003; 24: 415-20
36. Butterfield DA, Drake J, Pocernich C, et al. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med 2001; 7: 548-54
37. Varadarajan S, Kanski J, Aksenova M, et al. Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's A beta(1-42) and A beta(25-35). J Am Chem Soc 2001; 123: 5625-31
38. Butterfield DA, Lauderback CM. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid-peptide-associated free radical oxidative stress. Free Radic Biol Med 2002; 32: 1050-60
39. Butterfield DA, Castegna A, Lauderback CM, et al. Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contributes to neuronal death. Neurobiol Aging 2002; 23: 655-64
40. Lauderback CM, Hackett JM, Huang FF, et al. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Aβ1-42. J Neurochem 2001; 78: 413-6
41. Aksenov MY, Aksenova MV, Carney JM, et al. Oxidative modification of glutamine synthetase by amyloid beta peptide. Free Radic Res 1997; 27: 267-81
42. Butterfield DA, Hensley K, Cole P, et al. Oxidatively induced structural alteration of glutamine synthetase assessed by analysis of spin label incorporation kinetics: relevance to Alzheimer's disease. J Neurochem 1997; 68: 2451-7
43. Mattson MP, Cheng B, Culwell AR, et al. Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron 1993; 10: 243-54
44. Culcasi M, Lafon-Cazal M, Pietri S, et al. Glutamate receptors induce a burst of superoxide via activation of nitric oxide synthase in arginine-depleted neurons. J Biol Chem 1994; 269: 12589-93
45. Kennedy MB. Signal-processing machines at the postsynaptic density. Science 2000; 290: 750-4
46. Sheng M, Kim MJ. Postsynaptic signaling and plasticity mechanisms. Science 2002; 298: 776-80
47. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 2002; 298: 789-91
48. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30: 572-80
49. Davies CA, Mann DM, Sumpter PQ, et al. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J Neurol Sci 1987; 78: 151-64
50. Collingridge GL, Singer W. Excitatory amino acid receptors and synaptic plasticity. Trends Pharmacol Sci 1990; 11: 290-6
51. Myhrer T. Adverse psychological impact, glutamatergic dysfunction, and risk factors for Alzheimer's disease. Neurosci Biobehav Rev 1998; 23: 131-9
52. Furuta A, Rothstein JD, Martin JL. Glutamate transporter protein subtypes are expressed differentially during rat central nervous system development. J Neurosci 1997; 17: 8363-75
53. Sims KD, Robinson MB. Expression patterns and regulation of glutamate transporters in the developing and adult nervous system. Crit Rev Neurobiol 1999; 13: 169-97
54. Lehre KP, Levy LM, Otterson OP. et al. Differential expression of two glial glutamate transporters in the rat brain: quantitative and immunocytochemical observations. J Neurosci 1995; 15: 1835-53
55. Greenamyre JT, Young AB. Excitatory amino acids and Alzheimer's disease. Neurobiol Aging 1989; 10: 593-602
56. Gordon-Krajcer W, Salinska E, Lazarewicz JW. N-methyl-d-aspartate receptor-mediated processing of beta-amyloid precursor protein in rat hippocampal slices: in vitro-superfusion study. Folia Neuropathol 2002; 40: 13-7
57. Kamenetz F, Tomita T, Hsieh H, et al. APP processing and synaptic function. Neuron 2003; 37: 925-37
58. Raymond CR, Ireland DR, Abraham WC. NMDA receptor regulation by amyloid-beta does not account for its inhibition of LTP in rat hippocampus. Brain Res 2003; 968: 263-72
59. Greenamyre JT. The role of glutamate in neurotransmission and neurologic disease. Arch Neurol 1986; 43: 1058-63
60. Maragos WF, Greenamyre JT, Penney JB, et al. Glutamate dysfunction in Alzheimer's disease: an hypothesis. TINS 1987; 10: 65-8
61. Palmer AM, Gershon S. Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic? FASEB J 1990; 4: 2745-52
62. H-MRS at 0.5T. Neurology 2001; 56: 737-42
63. Moats RA, Ernst T, Shonk TK, et al. Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magn Reson Med 1994; 32: 110-5
64. Ernst T, Chang L, Melchor R, et al. Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. Radiology 1997; 203: 829-36
65. Castegna A, Aksenov M, Aksenova M, et al. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med 2002; 33: 562-71
66. Hensley K, Hall N, Subramaniam R, et al. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem 1995; 65: 2146-56
67. Butterfield DA. Beta-amyloid-associated free radical oxidative stress and neurotoxicity: implications for Alzheimer's disease. Chem Res Toxicol 1997; 10: 495-506
68. Masliah E, Alford M, DeTeresa R, et al. Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. Ann Neurol 1996; 40: 759-66
69. Scott HL, Tannenberg A, Dodd PR. Variant forms of neuronal glutamate transporter sites in Alzheimer's disease cerebral cortex. J Neurochem 1995; 64: 2193-202
70. Butterfield DA, Hensley K, Harris M, et al. beta-Amyloid peptide free radical fragments initiate synaptosomal lipoperoxidation in a sequence-specific fashion: implications to Alzheimer's disease. Biochem Biophys Res Commun 1994; 200 (2): 710-5
71. Thal DR. Excitatory amino acid transporter EAAT-2 in tangle-bearing neurons in Alzheimer's disease. Brain Pathol 2002; 12: 405-11
72. Boissiere F, Faucheux B, Duyckaerts C, et al. Striatal expression of glutamic acid decarboxylase gene in Alzheimer's disease. Neurochem 1998; 71: 767-74
73. Hertz L, Drejer J, Schousboe A. Energy metabolism in glutamatergic neurons, GABAergic neurons and astrocytes in primary cultures. Neurochem Res 1988; 13: 605-10
74. Marczynski TJ. GABAergic deafferentation hypothesis of brain aging and Alzheimer's disease revisited. Brain Res Bull 1998; 45: 341-79
75. Haug LS, Ostvold AC, Cowburn RF, et al. Decreased inositol (1,4,5)-trisphosphate receptor levels in Alzheimer's disease cerebral cortex: selectivity of changes and possible correlation to pathological severity. Neurodegeneration 1996; 5: 169-76
76. Kowall NW, Beal MF. Glutamate-, glutaminase-, and taurine-immunoreactive neurons develop neurofibrillary tangles in Alzheimer's disease. Ann Neurol 1991; 29: 162-7
77. Olney JW, Wozniak DF, Farber NB. Excitotoxic neurodegeneration in Alzheimer's disease: new hypothesis and new therapeutic strategies. Arch Neurol 1997; 54: 1234-40
78. Drake J, Kanski J, Varadarajan S, et al. Elevation of brain glutathione by glutamylcysteine ethyl ester protects against peroxynitrite-induced oxidative stress. J Neurosci Res 2002; 68: 776-84
79. Butterfield DA, Pocernich CB, Drake J. Elevated glutathione as a therapeutic strategy in Alzheimer's disease. Drug Dev Res 2002; 56: 428-37
80. Pocernich CB, Cardin AL, Racine CL, et al. Glutathione elevation and its protective role in acrolein-induced protein damage in synaptosomal membranes: relevance to brain lipid peroxidation in neurodegenerative disease. Neurochem Int 2001; 39 (2): 141-9
81. Butterfield DA, Castenga A, Pocernich CB, et al. Nutritional approaches to combat oxidative stress in Alzheimer's disease brain. J Nutr Biochem 2002; 13: 444-8
82. Butterfield DA, Castegna A, Drake J, et al. Vitamin E and neurodegenerative disorders associated with oxidative stress. Nutr Neurosci 2002; 5: 229-39
83. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease: the Alzheimer's Disease Cooperative Study. N Engl J Med 1997; 336: 1216-22
84. Onofrj M, Thomas A, Luciano AL, et al. Donepezil versus vitamin E in Alzheimer's disease. Part 2: mild versus moderate-severe Alzheimer's disease. Clin Neuropharmacol 2002; 25: 207-15
85. Adair JC, Knoefel JE, Morgan N. Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease. Neurology 2001; 57: 1515-7
86. Gandolfi O, Bonfante V, Voltattorni M, et al. Anticonvulsant preclinical profile of CHF 3381: dopaminergic and glutamatergic mechanisms. Pharmacol Biochem Behav 2001; 70: 157-66
87. Coughenour LL, Barr BM. Use of trifluoroperazine isolates a [(3)H]ifenprodil binding site in rat brain membranes with the pharmacology of the voltage-independent ifenprodil site on N-methyl-D-aspartate receptors containing NR2B subunits. J Pharmacol Exp Ther 2001; 296: 150-9
88. Rubin MA, Stiegemeier JA, Volkweis MA, et al. Intra-amygdala spermidine administration improves inhibitory avoidance performance in rats. Eur J Pharmacol 2001; 423: 35-9
89. Zhang YH, Zhao XY, Chen XQ, et al. Spermidine antagonizes the inhibitory effect of huperzine A on [3H]dizocilpine (MK-801) binding in synaptic membrane of rat cerebral cortex. Neurosci Lett 2002; 319: 107-10
90. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist: a review of preclinical data. Neuropharmacology 1999; 38: 735-67
91. Leppik IE, Marienau K, Graves NM, et al. MK-801 for epilepsy: a pilot study [abstract]. Neurology 1988; 38: 405
92. Sveinbjornsdottir S, Sander JWAS, Upton D, et al. The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy. Epilepsy Res 1993; 16: 165-74
93. Yenari MA, Bell TE, Kotake AN, et al. Dose escalation safety and tolerance study of the competitive NMDA antagonist selfotel (CGS 19755) in neurosurgery patients. Clin Neuropharmacol 1998; 21: 28-34
94. Barnes CA, Danysz W, Parsons CG. Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. Eur J Neurosci 1996; 8: 565-71
95. Zajaczkowski W, Quack G, Danysz W. Infusion of (+)-MK-801 and memantine: contrasting effects on radial maze learning in rats with entorhinal cortex lesion. Eur J Pharmacol 1996; 296: 239-46
96. Miguel-Hidalgo JJ, Alvarez XA, Cacabelos R, et al. Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40). Brain Res 2002; 958: 210-21
97. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999; 14: 135-46
98. Jarvis B, Figgitt D. Memantine. Drugs Aging 2003; 20: 465-76
99. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348: 1333-41
100. Wimo A, Winblad B, Stoffler A, et al. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics 2003; 21: 327-40
101. Ferris SH, Schmidt F, Doody R, et al. Long-term treatment with the NMDA antagonist, memantine: results of a 24-week, open-label extension study in advanced Alzheimer's disease [poster]. Annual Meeting of the American College of Neuropsychopharmacology; 2001 Dec 9-13; Waikoloa Village (HI)
102. Kilpatrick GJ, Tilbrook GS. Memantine: Merz. Curr Opin Investig Drugs 2002; 3: 798-806
103. Jain KK. Evaluation of memantine for neuroprotection in dementia. Expert Opin Investig Drugs 2000; 9: 1397-406
104. Wenk GL, Quack G, Moebius HJ, et al. No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. Life Sci 2000; 66: 1079-83
105. Farlow MR, Tariot PN, Grossberg GT, et al. Memantine/donepezil dual therapy is superior to placebo/donepezil therapy for treatment of moderate to severe Alzheimer's disease [abstract no. 1035]. Neurology 2003; 60 Suppl. 1: A412
106. Danysz W, Parsons CG, Jirgensons A, et al. Amino-alkyl-cyclohexanes as a novel class of uncompetitive NMDA receptor antagonists. Curr Pharm Des 2002; 8: 835-43
107. Liang Z, Valla J, Sefidvash-Hockley S, et al. Effects of estrogen treatment on glutamate uptake in cultured human astrocytes derived from cortex of Alzheimer's disease patients. J Neurochem 2002; 80: 807-14
108. Xu H, Gouras GK, Greenfield JP, et al. Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nat Med 1998; 4: 447-51
109. Li R, Shen Y, Yang L-B, et al. Estrogen enhances uptake of amyloid protein by microglia derived from the human cortex. J Neurochem 2000; 75: 14447-54
110. Zheng H, Xu H, Uljon SN, et al. Modulation of A(beta) peptides by estrogen in mouse models. J Neurochem 2002; 80: 191-6
111. Keller JN, Germeyer A, Begley JG, et al. 17-Estradiol attenuates oxidative impairment of synaptic Na/K-ATPase activity, glucose transport, and glutamate transport induced by amyloid b-peptide and ion. J Neurosci Res 1997; 50: 522-30
112. Trotti D, Danbolt NC, Volterra A. Glutamate transporters are oxidant-vulnerable: a molecular link between oxidative and excitotoxic neurodegeneration? Trends Pharmacol Sci 1998; 19: 328-34
113. Singer C, Rogers KL, Strickland TM, et al. Estrogen protects primary cortical neurons from glutamate toxicity. Neurosci Lett 1996; 212: 13-6
114. Green PS, Perez EJ, Calloway T, et al. Estradiol attenuation of beta-amyloid-induced toxicity: a comparison of MTT and calcein AM assays. J Neurocytol 2000; 29: 419-23
115. Asthana S, Craft S, Baker LD, et al. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study. Psychoneuroendocrinology 1999; 24: 657-77
116. Asthana S, Baker LD, Craft S, et al. High-dose estradiol improves cognition for women with AD: results of a randomized study. Neurology 2001; 57: 605-12
117. Yoon BK, Kim DK, Kang Y, et al. Hormone replacement therapy in postmenopausal women with Alzheimer's disease: a randomized, prospective study. Fertil Steril 2003; 79: 274-80
118. Thal LJ, Thomas RG, Mulnard R, et al. Estrogen levels do not correlate with improvement in cognition. Arch Neurol 2003; 60: 209-12
119. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial: Alzheimer's Disease Cooperative Study. JAMA 2000; 283: 1007-15
120. Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology 2000; 54: 295-301
121. Rigaud AS, Andre G, Vellas B, et al. No additional benefit of HRT on response to rivastigmine in menopausal women with AD. Neurology 2003; 60: 148-9
122. Owens CT. Estrogen replacement therapy for Alzheimer disease in postmenopausal women. Ann Pharmacother 2002; 36: 1273-6
123. Shumaker SA, Reboussin BA, Espeland MA, et al. The Women's Health Initiative Memory Study (WHIMS): a trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. Control Clin Trials 1998; 19: 604-21
124. MacLennan AH, Paine BJ, Marley JE. WISDOM: will Australian women participate? Aust Fam Physician 2000; 29: 797-801
125. Myhrer T. Animal models of Alzheimer's disease: glutamatergic denervation as an alternative approach to cholinergic denervation. Neurosci Biobehav Rev 1993; 17: 192-202
126. Steele JE, Palmer AM, Stratmann GC, et al. The N-methyl-D-aspartate receptor complex in Alzheimer's disease: reduced regulation by glycine but not zinc. Brain Res 1989; 500: 369-73
127. Herting RL. Milacemide and other drugs active at glutamate NMDA receptors as potential treatment for dementia. Ann N Y Acad Sci 1991; 640: 237-40
128. Schwartz BL, Hashtroudi RL, Herting H, et al. Glycine prodrug facilitates memory retrieval in humans. Neurology 1991; 41: 1341-3
129. Flood JF, Morley JE, Lanthorn TH. Effect on memory processing by D-cycloserine, an agonist of the NMDA/glycine receptor. Eur J Pharmacol 1992; 221: 249-54
130. Monahan JB, Handelmann GE, Hood WF, et al. D-cycloserine, a positive modulator of the N-methyl-D-aspartate receptor enhances performance of learning tasks in rats. Pharmacol Biochem Behav 1989; 34: 649-53
131. Chessell IP, Proctor AW, Francis PT, et al. D-cycloserine, a putative cognitive enhancer, facilitates activation of N-methyl-D-aspartate receptor-ionophore complex in Alzheimer brain. Brain Res 1991; 565: 345-8
132. Schwartz BL, Hashtroudi S, Herting RL, et al. D-cycloserine enhances implicit memory in Alzheimer patients. Neurology 1996; 46: 420
133. Shimada A, Spangler EL, London ED, et al. Spermidine potentiates dizocilpine-induced impairment of learning performance by rats in a 14-unit T-maze. Eur J Pharmacol 1994; 263: 293-30
134. Zhang S, Kashii S, Yasuyoshi H, et al. Protective effects of ifenprodil against glutamate-induced neurotoxicity in cultured retinal neurons. Graefes Arch Clin Exp Ophthalmol 2000; 238: 846-52
135. Gmiro VE, Serdiuk SE. Bis-ammonium adamantane derivatives: novel modulators of polyamine binding sites. Eksp Klin Farmakol 2000; 63: 16-20
136. Yatin SM, Yatin M, Varadarajan S, et al. Role of spermine in amyloid beta-peptide-associated free radical-induced neurotoxicity. J Neurosci Res 2001; 63: 395-401
137. Guldbrandt M, Johansen TN, Frydenvang K, et al. Glutamate receptor ligands: synthesis, stereochemistry, and enantiopharmacology of methylated 2-aminoadipic acid analogs. Chirality 2002; 14: 351-63